The 2020 update highlights the importance of accurate diagnosis of upper tract urothelial carcinoma, risk stratification, close follow-up of patients receiving kidney-sparing management, and other key aspects of care.
The FDA has approved Bavencio® (avelumab; EMD Serono) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
A study found no survival differences between high-grade UTUC patients who at the time of radical nephroureterectomy achieved low-grade disease following neoadjuvant chemotherapy and those who had inherently low-stage disease and did not receive chemotherapy.
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.